新视野:甲状腺癌新兴疗法与靶点
本文讨论对标准治疗无反应的进展性转移性滤泡细胞来源和髓样甲状腺癌的治疗挑战。随着对分子驱动因素的理解加深及更有效特异性化合物的开发,FDA批准的甲状腺癌治疗数量增加,疾病不可知靶向批准拓宽了选择。但完全缓解罕见、平均缓解持续时间有限且毒性常见,需进一步理解耐药机制、开发生物标志物并持续探索新策略。
要点
- 进展性转移性甲状腺癌对标准治疗无反应时治疗选择有限。
- FDA批准的甲状腺癌治疗数量增加,疾病不可知靶向批准拓宽选择。
- 完全缓解罕见、缓解持续时间有限且毒性常见,需新策略。
核心结论
- 甲状腺癌治疗选择增多但完全缓解罕见、缓解持续时间有限且毒性常见,需深入理解耐药机制并开发新策略。
主要发现
- 对标准治疗无反应的进展性转移性滤泡细胞来源和髓样甲状腺癌构成治疗挑战。
- FDA批准的甲状腺癌治疗数量已扩大,疾病不可知靶向批准使治疗选择不断拓宽。
- 完全缓解罕见,平均缓解持续时间相对有限,毒性常见。
临床怎么用
- 临床需关注耐药机制以应对治疗失败。
- 开发生物标志物以改善疾病早期患者选择。
- 持续探索新的治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The treatment of patients with progressive metastatic follicular cell-derived and medullary thyroid cancers that do not respond to standard therapeutic modalities presents a therapeutic challenge. As a deeper understanding of the molecular drivers for these tumors has occurred and more potent and specific compounds are developed, the number of Food and Drug Administration (FDA)-approved treatments for thyroid cancer has expanded. In addition, with the advent of disease-agnostic target-directed FDA approvals an ever-broadening number of therapeutic options are available for clinicians and patients. However, to date, complete remissions are rare, the average durations of response are relatively modest, and toxicities are common. These factors accentuate the need for further understanding of the mechanisms of resistance that result in treatment failures, the development of biomarkers that can improve patient selection for treatment earlier in the disease process, and the continued need for new therapeutic strategies. In this article, recent approvals relevant to thyroid cancer will be discussed along with selected new potential avenues that might be exploited for future therapies.
引用
- Ringel MD. New Horizons: Emerging Therapies and Targets in Thyroid Cancer. J Clin Endocrinol Metab. 2021. PMID: 32977343. doi:10.1210/clinem/dgaa687
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。